Boehringer Ingelheim
For Healthcare Professionals

ACT SMART Q

rtPA Use Without Visible Occlusion | Dr. Tan Wee Yong

19/05/2025  |  Author: Boehringer Ingelheim

Document ID: PC-SG-102811

ACTILYSE 50mg

ACT SMART Q: Network Approach in Stroke Care
How to Use the Modified Rankin Scale | Dr. Tan Wee Yong
The Efficacy and Safety Profile of Actilyse
Bleeding Rates of Alteplase | Dr. Tan Wee Yong
Post-rtPA Symptoms to Monitor | Dr. Tan Wee Yong
rtPA Use Without Visible Occlusion | Dr. Tan Wee Yong
Managing Post-rtPA ICH in Stroke | Dr. Tan Wee Yong
AIS Early Management Guidelines | Dr. Macrohon Valdez
Early Treatment in AIS Matters | Dr. Macrohon Valdez
Alteplase Dosing in Stroke Care | Dr. Macrohon Valdez
Role of Alteplase | Alteplase Use in Young & Old Stroke
Understanding NIHSS Score Limits | Dr. Macrohon Valdez
Essential Setup Without Specialists for Stroke Units
Bridging Therapy and Sweet Spot to Use Alteplase
Stroke Fast Track (SFT) | Emergency Stroke Care System
ACT SMART Q: Improving Stroke Care in Thailand

RELATED CONTENT